These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15707727)

  • 1. In vitro and in vivo percutaneous absorption of topical dosage forms: case studies.
    Csóka I; Csányi E; Zapantis G; Nagy E; Fehér-Kiss A; Horváth G; Blazsó G; Eros I
    Int J Pharm; 2005 Mar; 291(1-2):11-9. PubMed ID: 15707727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of ketamine systemic absorption from topical preparations. Short Communication.
    Zapantis G; Csóka I; Csányi E; Horváth G; Erös I
    Acta Biol Hung; 2006 Sep; 57(3):387-9. PubMed ID: 17048702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and characterization of reverse micelle based organogels of piroxicam.
    Agrawal GP; Juneja M; Agrawal S; Jain SK; Pancholi SS
    Pharmazie; 2004 Mar; 59(3):191-3. PubMed ID: 15074590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of cyclodextrin complexation on piroxicam gel formulations.
    Jug M; Bećirević-Laćan M; Kwokal A; Cetina-Cizmek B
    Acta Pharm; 2005 Sep; 55(3):223-36. PubMed ID: 16375834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
    Prabhu S; Ortega M; Ma C
    Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rheological characterization and in vivo evaluation of thermosensitive poloxamer-based hydrogel for intramuscular injection of piroxicam.
    Xuan JJ; Balakrishnan P; Oh DH; Yeo WH; Park SM; Yong CS; Choi HG
    Int J Pharm; 2010 Aug; 395(1-2):317-23. PubMed ID: 20573569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid-state dependent dissolution and oral bioavailability of piroxicam in rats.
    Lust A; Laidmäe I; Palo M; Meos A; Aaltonen J; Veski P; Heinämäki J; Kogermann K
    Eur J Pharm Sci; 2013 Jan; 48(1-2):47-54. PubMed ID: 23085546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam.
    Prajapati RN; Tekade RK; Gupta U; Gajbhiye V; Jain NK
    Mol Pharm; 2009; 6(3):940-50. PubMed ID: 19231841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation and evaluation of once-a-day transdermal gels of diclofenac diethylamine.
    Baboota S; Shakeel F; Kohli K
    Methods Find Exp Clin Pharmacol; 2006 Mar; 28(2):109-14. PubMed ID: 16636721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate.
    Ambrogi V; Perioli L; Marmottini F; Giovagnoli S; Esposito M; Rossi C
    Eur J Pharm Sci; 2007 Nov; 32(3):216-22. PubMed ID: 17826966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New formulation of in situ gelling Metolose-based liquid suppository.
    Pásztor E; Makó A; Csóka G; Fenyvesi Z; Benko R; Prosszer M; Marton S; Antal I; Klebovich I
    Drug Dev Ind Pharm; 2011 Jan; 37(1):1-7. PubMed ID: 21073325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the surfactant on the availability of piroxicam as a poorly hydrosoluble drug from suppositories.
    Dal Zorro M; Franceschinis E; Punchina A; Realdon N
    Pharmazie; 2012 Jan; 67(1):37-45. PubMed ID: 22393829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
    Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
    Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrathecal antinociceptive interaction between the NMDA antagonist ketamine and the opioids, morphine and biphalin.
    Kosson D; Klinowiecka A; Kosson P; Bonney I; Carr DB; Mayzner-Zawadzka E; Lipkowski AW
    Eur J Pain; 2008 Jul; 12(5):611-6. PubMed ID: 18068383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro release and antiinflammatory activity of topical formulations of ketoprofen.
    Moretti MD; Gavini E; Peana AT
    Boll Chim Farm; 2000; 139(2):67-72. PubMed ID: 10920531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced bioavailability of piroxicam via salt formation with ethanolamines.
    Gwak HS; Choi JS; Choi HK
    Int J Pharm; 2005 Jun; 297(1-2):156-61. PubMed ID: 15907602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation of meloxicam gel for topical application: In vitro and in vivo evaluation.
    Bachhav YG; Patravale VB
    Acta Pharm; 2010 Jun; 60(2):153-63. PubMed ID: 21134852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketamine and lornoxicam for preventing a fentanyl-induced increase in postoperative morphine requirement.
    Xuerong Y; Yuguang H; Xia J; Hailan W
    Anesth Analg; 2008 Dec; 107(6):2032-7. PubMed ID: 19020155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transbuccal permeation, anti-inflammatory activity and clinical efficacy of piroxicam formulated in different gels.
    Attia MA; El-Gibaly I; Shaltout SE; Fetih GN
    Int J Pharm; 2004 May; 276(1-2):11-28. PubMed ID: 15113610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of dissolution and bioavailability of piroxicam in solid dispersion systems.
    Pan RN; Chen JH; Chen RR
    Drug Dev Ind Pharm; 2000 Sep; 26(9):989-94. PubMed ID: 10914324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.